SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-164890
Filing Date
2023-06-12
Accepted
2023-06-12 07:00:53
Documents
14
Period of Report
2023-06-11
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d517852d8k.htm   iXBRL 8-K 45955
2 EX-99.1 d517852dex991.htm EX-99.1 35932
6 GRAPHIC g517852g94y20.jpg GRAPHIC 15288
  Complete submission text file 0001193125-23-164890.txt   238988

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20230611.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20230611_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20230611_pre.xml EX-101.PRE 11259
8 EXTRACTED XBRL INSTANCE DOCUMENT d517852d8k_htm.xml XML 3351
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 231007069
SIC: 2835 In Vitro & In Vivo Diagnostic Substances